Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Neuroinflammation, AD, and Dementia.

Reale M, Brenner T, Greig NH, Inestrosa N, Paleacu D.

Int J Alzheimers Dis. 2010 Sep 7;2010. pii: 974026. doi: 10.4061/2010/974026. No abstract available.

2.

Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease.

Agostinho P, Cunha RA, Oliveira C.

Curr Pharm Des. 2010;16(25):2766-78. Review.

PMID:
20698820
3.

Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation.

Ernst A, Buerger K, Hartmann O, Dodel R, Noelker C, Sommer N, Schwarz M, Köhrle J, Bergmann A, Hampel H.

J Neuroimmunol. 2010 Apr 15;221(1-2):62-7. doi: 10.1016/j.jneuroim.2010.02.004. Epub 2010 Mar 5.

PMID:
20207019
4.

Inflammation and Alzheimer's disease.

Lee YJ, Han SB, Nam SY, Oh KW, Hong JT.

Arch Pharm Res. 2010 Oct;33(10):1539-56. doi: 10.1007/s12272-010-1006-7. Epub 2010 Oct 30. Review.

PMID:
21052932
5.

Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation.

Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM.

J Mol Neurosci. 2004;24(1):115-22.

PMID:
15314259
6.

Effect of anti-dementia drugs on LPS induced neuroinflammation in mice.

Tyagi E, Agrawal R, Nath C, Shukla R.

Life Sci. 2007 May 1;80(21):1977-83. Epub 2007 Mar 12.

PMID:
17395211
7.

Anticholinergic drug use and risk for dementia: target for dementia prevention.

Jessen F, Kaduszkiewicz H, Daerr M, Bickel H, Pentzek M, Riedel-Heller S, Wagner M, Weyerer S, Wiese B, van den Bussche H, Broich K, Maier W.

Eur Arch Psychiatry Clin Neurosci. 2010 Nov;260 Suppl 2:S111-5. doi: 10.1007/s00406-010-0156-4. Epub 2010 Oct 20.

PMID:
20960005
8.

Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease.

Shie FS, Woltjer RL.

Curr Med Chem. 2007;14(27):2865-71. Review.

PMID:
18045132
9.

[Is hippocampal atrophy a specific change for Alzheimer's disease?].

Hanyu H, Asano T, Sakamoto S, Kogure D, Iwamoto T, Takasaki M.

No To Shinkei. 1999 Nov;51(11):947-51. Japanese.

PMID:
10586410
10.

Alzheimer disease and the dementia of Parkinson disease: comparative investigations.

Mahler ME, Cummings JL.

Alzheimer Dis Assoc Disord. 1990 Fall;4(3):133-49. Review.

PMID:
1977419
11.

Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies.

Hansen LA, Samuel W.

Neurology. 1997 Jan;48(1):126-32.

PMID:
9008507
12.

Risk and protective factors for sporadic Alzheimer's disease.

Stozická Z, Zilka N, Novák M.

Acta Virol. 2007;51(4):205-22. Review.

PMID:
18197729
13.

Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment.

Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, Luck T, Mösch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H; German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group.

Arch Gen Psychiatry. 2010 Apr;67(4):414-22. doi: 10.1001/archgenpsychiatry.2010.30.

PMID:
20368517
14.

Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study.

Sundelöf J, Kilander L, Helmersson J, Larsson A, Rönnemaa E, Degerman-Gunnarsson M, Basun H, Lannfelt L, Basu S.

J Alzheimers Dis. 2009;18(1):79-87. doi: 10.3233/JAD-2009-1126. Erratum in: J Alzheimers Dis. 2010;20(2):681.

PMID:
19542629
15.

Pharmacogenomics and therapeutic prospects in dementia.

Cacabelos R.

Eur Arch Psychiatry Clin Neurosci. 2008 Mar;258 Suppl 1:28-47. doi: 10.1007/s00406-007-1006-x. Review.

PMID:
18344047
16.

EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.

Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M.

Brain. 2008 Mar;131(Pt 3):690-705. doi: 10.1093/brain/awm322. Epub 2008 Jan 17.

PMID:
18202105
18.

Neuropsychological and behavioural correlates of CSF biomarkers in dementia.

Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Mariën P, De Deyn PP.

Neurochem Int. 2006 Mar;48(4):286-95. Epub 2006 Jan 24.

PMID:
16434124
19.

The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology.

Thal DR, Schultz C, Botez G, Del Tredici K, Mrak RE, Griffin WS, Wiestler OD, Braak H, Ghebremedhin E.

Neuropathol Appl Neurobiol. 2005 Jun;31(3):270-9.

PMID:
15885064
20.

Classification of vascular dementia in the Cardiovascular Health Study Cognition Study.

Lopez OL, Kuller LH, Becker JT, Jagust WJ, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Kawas C, Carlson M.

Neurology. 2005 May 10;64(9):1539-47.

PMID:
15883314

Supplemental Content

Support Center